Abstract:Objectives We aim to explore the incidence and risk factors of AF, dangerous ventricular arrhythmias and bradyarrhythmia in patients with HCM, and improve the awareness of clinicians on hypertrophic cardiomyopathy (HCM) associated with life-threatening arrhythmias. Methods We retrospectively collected the clinical data of 86 unrelated patients diagnosed as HCM in our hospital from January 2009 to January 2012, including each patient9s personal characteristics, clinical manifestations, echocardiography, 12-lead electrocardiography(ECG), 24 h Holter ECG monitoring, coronary angiography, left ventricular angiography and related treatment. Results 1. In 86 patients with HCM, male and female patients were 56 and 30, respectively, and mean age was 58.4±14.3 years. 2. 21 patients (24.4%) had documented AF, 7 patients with paroxysmal AF and 14 patients with chronic AF. 72 patients (85.7%) had premature ventricular contractions (PVCs), 36 patients (41.9%) had PVCs with Low grade ≥3, and 22 patients (25.6%) had non-sustained ventricular tachycardia (NSVT). eight patients (9.3%) had sick sinus syndrome (SSS), 11 patients (12.8%) had atrioventricular block (AVB) and nine patients (10.5%) had atrial fibrillation with slow ventricular rate and long RR interval (RR interval >2.0 s). 3. The mean age at examination was 64.1±11.0 years in patients with AF, older than those with sinus rhythm (56.6±14.8 years) (p=0.037). Left atrial diameter (LAD) was greater in patients with AF than those without AF (45.3±5.2 mm vs 40.2±5.2 mm) (p<0.01). There were 8 cases (38.1%) in NYHA classes III and IV in AF group, more than those without AF (6.2%, p=0.001). And left ventricular ejection fraction (LVEF) in AF group was lower than those without AF (64.8±9.7% vs 69.4±8.1%, p=0.036). 4. Maximum left ventricular wall thickness (MLVWT) and LAD was greater in patients with dangerous ventricular arrhythmias (B group) than in patients without dangerous ventricular arrhythmias (A group) (23.1±5.4 mm vs 20.2±4.9 mm and 42.8±5.2 mm vs 40.4±5.8 mm, p=0.009 and 0.048, respectively). The incidence of AF in B group was significantly higher than in A group (36.1% vs 16.0%, p<0.05). 5. In patients with pacemaker implantation, the age (mean 67.6±7.4 years) was older than those without pacemaker implantation (mean 55.5±14.1 years, p=0.01). LVEF in patients with pacemaker implantation was significantly lower than in patients without pacemaker implantation (64.0±10.0% vs 69.3±8.1%, p=0.024). And the incidence of AF in patients with pacemaker implantation was significantly higher than in patients without pacemaker implantation (52.9% vs 17.4%, p<0.05). Conclusions Our study showed the incidence of arrhythmias in patients with HCM, including AF, dangerous ventricular arrhythmias and bradyarrhythmia, was quite high. And the incidence of AF and bradyarrhythmia was positively correlated with age increasing. The occurrence of AF was significantly associated with LAD, cardiac dysfunction and age. The prevalence of dangerous ventricular arrhythmias was 41.9%, and its occurrence was associated with MLVWT and LAD. LVEF was significantly decreased in patients with pacemaker implantation. The prevalence of AF in patients with dangerous ventricular arrhythmias and bradyarrhythmia was much higher than others without dangerous ventricular arrhythmias and bradyarrhythmia. Therefore, AF might play an important role in the prognosis of HCM patients.

Clinical and echographic parameters as risk factors for atrial fibrilation in patients with hypertophic cardiomyopathy

Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High‐Risk Population

Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review

PREVALENCE AND RELATED FACTORS OF ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

Hypertrophic cardiomyopathy and atrial fibrillation: the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology

Atrial Fibrillation in Hypertrophic Cardiomyopathy

Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data

Influence of atrial fibrillation on long-term prognosis of patients with hypertrophic cardiomyopathy

Clinical and pathophysiologic determinants of catheter ablation outcome in hypertrophic cardiomyopathy with atrial fibrillation

Prevalence of atrial myopathy among hypertrophic cardiomyopathy patients without atrial fibrillation

From atrial fibrillation management to atrial myopathy assessment: the evolving concept of left atrium disease in hypertrophic cardiomyopathy

Association between the Albumin-to-Globulin Ratio and Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study

PS-C02-5: HYPERTENSION IS NOT A PREDICTOR OF ATRIAL FIBROSIS IN PATIENTS WITH ATRIAL FIBRILLATION - EVIDENCE FROM ATRIAL BIOPSY

Prediction Of Atrial Fibrillation Development And Progression: Current Perspectives

Long-term efficacy and safety of ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy

Clinical Course and Treatment of Patients With Apical Aneurysms Due to Hypertrophic Cardiomyopathy

Characteristics of heart rate variability in patients with hypertrophic cardiomyopathy complicated with atrial fibrillation

Electrophysiological and Structural Remodeling of the Atria in a Mouse Model of Troponin-I Mutation Linked Hypertrophic Cardiomyopathy: Implications for Atrial Fibrillation

Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy

Segmental myocardial tissue remodeling and atrial arrhythmias in hypertrophic cardiomyopathy: Findings from T1-mapping MRI